We partner with patient organizations to meaningfully impact medicine’s development and the patient care pathway.
A structured, compliant, efficient, and low-burden mechanism is needed to provide a forum for patients to share their experiences and help to co-create more effective and efficient therapies with innovators, researchers and other key stakeholders, such as regulators, health system leaders, policymakers, and payers.
Our approach is global, transformative and sustainable.
Global Patient Dialogues: What are the benefits of our new patient engagement approach?
Current approaches to holding externally-led, voice-of-the-patient meetings are costly, inefficient, and slow. They place a high burden on patients and patient groups who are typically resource-constrained. They are time-consuming and burdensome because they require fundraising by patient groups to identify industry sponsors and contracts established among multiple patient groups and multiple funders.
These relationships may raise concerns about the independence of patient groups from influence by the companies involved. Because of these barriers, several industry leaders /stakeholders (including health system leaders) are engaging unaffiliated patients, therefore Patient Organization expertise is not optimized. The Global Patient Dialogue Series eliminates these hurdles for patient groups and stakeholders while delivering a sustainable solution to address the interest from regulators for patient organizations to identify and organize patient-focused collaborations to accelerate public input in multiple disease areas, using the process established through the FDA-PFDD as a model.
Patients provide insights on daily life with or trying to prevent specific medical conditions, interfacing with delivery systems, calculating benefit/risk decisions and specify the ultimate value of innovation.
National Glaucoma Awareness Month
American Heart Month
National Colorectal Cancer Awareness Month
Alcohol Awareness Month
ALS Awareness Month
Alzheimer’s and Brain Awareness Month
National HIV Awareness Month
National Immunization Awareness Month
Prostate Cancer Awareness Month
National Breast Cancer Awareness Month
Lung Cancer Awareness Month
World AIDS Day
Lead Partner Organization: Co- Founders: Jeanne M. Regnante, CEO & Adrienne G. Tilbor, DO, Chief Medical Officer have a combined 50+ year experience in health care, research innovation and global patient engagement. Our delivery team will secure the stakeholder-enabled process for dialogue implementation, drive logistics and coordination of roles for each patient dialogue with multiple stakeholder partners and ensure execution with excellence.
“One of the 21st Century pioneers of patient engagement practice in the Life Science Industry, Patient 3i leadership has done much to shape the environmental context and establish best practice in an actionable, impactful and sustainable way.”
"Bridging the chasm between patients’ needs and priorities and healthcare delivery is essential to ensuring effective, affordable products and services. Listening to and understanding patients’ experiences and challenges is the engine for developing new, viable healthcare solutions."
"Patient partnership in drug development is an absolute necessity, but the time and space necessary for meaningful collaboration is not a luxury many patients or other stakeholders have. Patient3i provides the forum for patient-centered, multi-stakeholder collaboration in the development of life-saving and quality of life-preserving therapies."
"Our ideals change as we expand our experiences. Our world becomes larger and more fascinating, and we find the courage to act on those new ideals. This is what Patient 3i will do for innovation!"
"Global Patient Dialogues creates a convenient, compliant listening forum for global innovators and patient communities to learn from each other directly!"
“Researchers and Innovators in Health Care will embrace a coordinated, efficient and trusted model driven by Patient Organization leadership, which defines relevant value for patients, informed by the latest regulatory guidance and patient engagement standards.”